# Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent

> **NCT05230940** · PHASE2 · COMPLETED · sponsor: **Health Institutes of Turkey** · enrollment: 1 (actual)

## Conditions studied

- COVID-19
- Sars-CoV-2 Infection

## Interventions

- **BIOLOGICAL:** TURKOVAC
- **BIOLOGICAL:** CoronaVac

## Key facts

- **NCT ID:** NCT05230940
- **Lead sponsor:** Health Institutes of Turkey
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2022-02-18
- **Primary completion:** 2023-05-15
- **Final completion:** 2024-02-08
- **Target enrollment:** 1 (ACTUAL)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05230940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05230940, "Efficacy, Immunogenicity, and Safety of TURKOVAC Vaccine Versus the CoronaVac Vaccine Against COVID-19 in Healthy Adolescent". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05230940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*